Literature DB >> 30409495

Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VI.

Min-Ju Chan1, Hsuan-Chieh Liao1, Michael H Gelb2, Chih-Kuang Chuang3, Mei-Ying Liu1, Hsiao-Jan Chen1, Shu-Min Kao1, Hsiang-Yu Lin4, You-Hsin Huang5, Arun Babu Kumar6, Naveen Kumar Chennamaneni6, Nagendar Pendem6, Shuan-Pei Lin3, Chuan-Chi Chiang7.   

Abstract

OBJECTIVE: To evaluate the initial cutoff values, rates of screen positives, and genotypes for the large-scale newborn screening program for multiple mucopolysaccharidoses (MPS) in Taiwan. STUDY
DESIGN: More than 100 000 dried blood spots were collected consecutively as part of the national Taiwan newborn screening programs. Enzyme activities were measured by tandem mass spectrometry from dried blood spot punches. Genotypes were obtained when a second newborn screening specimen again had a decreased enzyme activity. Additional clinical evaluation was then initiated based on enzyme activity and/or genotype.
RESULTS: Molecular genetic analysis for cases with low enzyme activity revealed 5 newborns with pathogenic alpha-L-iduronidase mutations, 3 newborns with pathogenic iduronate-2-sulfatase mutations, and 1 newborn was a carrier of an arylsulfatase B mutation. Several variants of unknown pathogenic significance were also identified, most likely causing pseudodeficiency.
CONCLUSIONS: The highly robust tandem mass spectrometry-based enzyme assays for MPS-I, MPS-II, and MPS-VI allow for high-throughput newborn screening for these lysosomal storage disorders. Optimized cutoff values combined with second tier testing could largely eliminate false-positive results. Accordingly, newborn screening for these lysosomal storage disorders is possible.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mucopolysaccharidosis; inborn errors of metabolism; lysosomal storage disease; newborn screening; tandem mass spectrometry

Mesh:

Year:  2018        PMID: 30409495      PMCID: PMC6623979          DOI: 10.1016/j.jpeds.2018.09.063

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  45 in total

1.  Fabry disease: enzymatic diagnosis in dried blood spots on filter paper.

Authors:  N A Chamoles; M Blanco; D Gaggioli
Journal:  Clin Chim Acta       Date:  2001-06       Impact factor: 3.786

2.  Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper.

Authors:  Néstor A Chamoles; Gabriela Niizawa; Mariana Blanco; Daniela Gaggioli; Carina Casentini
Journal:  Clin Chim Acta       Date:  2004-09       Impact factor: 3.786

3.  Multiplex Tandem Mass Spectrometry Enzymatic Activity Assay for Newborn Screening of the Mucopolysaccharidoses and Type 2 Neuronal Ceroid Lipofuscinosis.

Authors:  Yang Liu; Fan Yi; Arun Babu Kumar; Naveen Kumar Chennamaneni; Xinying Hong; C Ronald Scott; Michael H Gelb; Frantisek Turecek
Journal:  Clin Chem       Date:  2017-04-20       Impact factor: 8.327

4.  The clinical and genetic Spectrum of Maroteaux-Lamy syndrome (Mucopolysaccharidosis VI) in the Eastern Province of Saudi Arabia.

Authors:  Nouriya Abbas Al-Sannaa; Hind Yousif Al-Abdulwahed; Sami Ibrahim Al-Majed; Issam Hassan Bouholaigah
Journal:  J Community Genet       Date:  2017-09-15

5.  A fluorometric assay using 4-methylumbelliferyl alpha-L-iduronide for the estimation of alpha-L-iduronidase activity and the detection of Hurler and Scheie syndromes.

Authors:  J J Hopwood; V Muller; A Smithson; N Baggett
Journal:  Clin Chim Acta       Date:  1979-03-01       Impact factor: 3.786

6.  A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease).

Authors:  Y V Voznyi; J L Keulemans; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  2001-11       Impact factor: 4.982

7.  Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry.

Authors:  Francyne Kubaski; Robert W Mason; Akiko Nakatomi; Haruo Shintaku; Li Xie; Naomi N van Vlies; Heather Church; Roberto Giugliani; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Tadao Orii; Toshiyuki Fukao; Adriana M Montaño; Shunji Tomatsu
Journal:  J Inherit Metab Dis       Date:  2016-10-07       Impact factor: 4.982

8.  Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004.

Authors:  Hsiang-Yu Lin; Shuan-Pei Lin; Chih-Kuang Chuang; Dau-Ming Niu; Ming-Ren Chen; Fuu-Jen Tsai; Mei-Chyn Chao; Pao-Ching Chiu; Shio-Jean Lin; Li-Ping Tsai; Wuh-Liang Hwu; Ju-Li Lin
Journal:  Am J Med Genet A       Date:  2009-05       Impact factor: 2.802

9.  MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes.

Authors:  Chang Chih-Kuang; Lin Shuan-Pei; Lee Shyue-Jye; Wang Tuen-Jen
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

10.  Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses.

Authors:  Hsiang-Yu Lin; Shou-Chuan Shih; Chih-Kuang Chuang; Ming-Ren Chen; Dau-Ming Niu; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2013-05-11       Impact factor: 4.123

View more
  22 in total

Review 1.  Newborn screening of mucopolysaccharidoses: past, present, and future.

Authors:  Nivethitha Arunkumar; Thomas J Langan; Molly Stapleton; Francyne Kubaski; Robert W Mason; Rajendra Singh; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2020-04-10       Impact factor: 3.172

2.  Newborn Screening for Mucopolysaccharidoses: Results of a Pilot Study with 100 000 Dried Blood Spots.

Authors:  Clifford Ronald Scott; Susan Elliott; Xinying Hong; Jie-Yu Huang; Arun Babu Kumar; Fan Yi; Nagendar Pendem; Naveen Kumar Chennamaneni; Michael H Gelb
Journal:  J Pediatr       Date:  2019-11-12       Impact factor: 4.406

Review 3.  Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.

Authors:  Kazuki Sawamoto; Molly Stapleton; Carlos J Alméciga-Díaz; Angela J Espejo-Mojica; Juan Camilo Losada; Diego A Suarez; Shunji Tomatsu
Journal:  Drugs       Date:  2019-07       Impact factor: 11.431

4.  A case study of three patients with mucopolysaccharidoses in Hue Central Hospital.

Authors:  Tran Kiem Hao; Nguyen Thi Diem Chi; Nguyen Thi Hong Duc; Nguyen Thi Kim Hoa
Journal:  SAGE Open Med Case Rep       Date:  2020-06-29

Review 5.  Emerging Approaches for Fluorescence-Based Newborn Screening of Mucopolysaccharidoses.

Authors:  Rajendra Singh; Shaileja Chopra; Carrie Graham; Melissa Langer; Rainer Ng; Anirudh J Ullal; Vamsee K Pamula
Journal:  Diagnostics (Basel)       Date:  2020-05-11

6.  Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I.

Authors:  Dawn S Peck; Jean M Lacey; Amy L White; Gisele Pino; April L Studinski; Rachel Fisher; Ayesha Ahmad; Linda Spencer; Sarah Viall; Natalie Shallow; Amy Siemon; J Austin Hamm; Brianna K Murray; Kelly L Jones; Dimitar Gavrilov; Devin Oglesbee; Kimiyo Raymond; Dietrich Matern; Piero Rinaldo; Silvia Tortorelli
Journal:  Int J Neonatal Screen       Date:  2020-02-07

Review 7.  Cardiac characteristics and natural progression in Taiwanese patients with mucopolysaccharidosis III.

Authors:  Hsiang-Yu Lin; Ming-Ren Chen; Shan-Miao Lin; Chung-Lieh Hung; Dau-Ming Niu; Tung-Ming Chang; Chih-Kuang Chuang; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

Review 8.  Zebrafish, an In Vivo Platform to Screen Drugs and Proteins for Biomedical Use.

Authors:  Hung-Chieh Lee; Cheng-Yung Lin; Huai-Jen Tsai
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-24

Review 9.  Biomarkers for Lysosomal Storage Disorders with an Emphasis on Mass Spectrometry.

Authors:  Ryuichi Mashima; Torayuki Okuyama; Mari Ohira
Journal:  Int J Mol Sci       Date:  2020-04-14       Impact factor: 5.923

Review 10.  Mucopolysaccharidosis Type I.

Authors:  Francyne Kubaski; Fabiano de Oliveira Poswar; Kristiane Michelin-Tirelli; Ursula da Silveira Matte; Dafne D Horovitz; Anneliese Lopes Barth; Guilherme Baldo; Filippo Vairo; Roberto Giugliani
Journal:  Diagnostics (Basel)       Date:  2020-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.